- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ARTELO BIOSCIENCES, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| Di | Artelo Biosciences erfüllt wieder NASDAQ-Börsenanforderungen | 1 | Investing.com Deutsch | ||
| Di | Artelo Biosciences regains Nasdaq listing compliance | 1 | Investing.com | ||
| Di | Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements | 78 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop... ► Artikel lesen | |
| Di | ARTELO BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| ARTELO BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 30.03. | Artelo Biosciences closes $11M private placement | 1 | Investing.com | ||
| 30.03. | Artelo Biosciences sichert sich 11 Mio. US-Dollar durch Privatplatzierung | 2 | Investing.com Deutsch | ||
| 30.03. | Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 27.03. | Privatplatzierung: Artelo Biosciences sichert sich 11 Millionen US-Dollar | 10 | Investing.com Deutsch | ||
| 27.03. | Artelo Biosciences raises $11 million in private placement | 1 | Investing.com | ||
| 27.03. | Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 241 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate... ► Artikel lesen | |
| 27.03. | Morning Market Movers: Artelo Biosciences, Onconetix, Datacentrex, Robin Energy See Big Swings | 517 | AFX News | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 26.03. | ARTELO BIOSCIENCES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 25.03. | Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments | 194 | GlobeNewswire (Europe) | Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH... ► Artikel lesen | |
| 25.03. | Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength | 371 | GlobeNewswire (Europe) | BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully... ► Artikel lesen | |
| 23.03. | ARTELO BIOSCIENCES, INC. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 20.03. | ARTELO BIOSCIENCES, INC. - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 18.03. | Nano-Cap Artelo Biosciences Stock Explodes - Glaucoma Study Collaboration Ignites Rally | 1 | Benzinga.com | ||
| 18.03. | Artelo Biosciences: Aktie legt nach Vereinbarung zu Glaukom-Studie kräftig zu | 3 | Investing.com Deutsch | ||
| 18.03. | Vanderbilt Report and Artelo Biosciences: Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,15 | -0,51 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| BB BIOTECH | 49,200 | +2,07 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| QIAGEN | 35,095 | +0,19 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,900 | +0,16 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| AMGEN | 303,30 | -0,18 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 7,310 | +0,27 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 291,70 | +0,66 % | Outset Medical adds former Stryker leader as new EVP of commercial | ||
| BIOGEN | 152,12 | +0,53 % | Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen | |
| ILLUMINA | 105,18 | -0,45 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,500 | +0,63 % | Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM | ||
| PALATIN TECHNOLOGIES | 18,650 | 0,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| AAP IMPLANTATE | 1,380 | +0,73 % | AAP Implantate AG zeigt strukturelle Stärke | ||
| OCUGEN | 1,626 | +0,87 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,930 | +2,14 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| BIONXT SOLUTIONS | 0,316 | +0,32 % | BioNxt sichert sich einheitliches europäisches Patent für seine sublinguale Cladribin-ODF-Plattform in 18 Ländern | VANCOUVER, BC / ACCESS Newswire / 7. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives Biowissenschaftsunternehmen, das
sich... ► Artikel lesen |
ARTELO BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,550 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTELO BIOSCIENCES INC finden Sie auf Wallstreet Online.